Keryx Biopharmaceuticals Stock Price, News & Analysis (NASDAQ:KERX)

$4.80 -0.12 (-2.44 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$4.92
Today's Range$4.77 - $4.99
52-Week Range$4.47 - $8.38
Volume1.71 million shs
Average Volume1.53 million shs
Market Capitalization$568.81 million
P/E RatioN/A
Dividend YieldN/A
Beta5.07

About Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:KERX
  • CUSIP: 49251510
  • Web: www.keryx.com
Debt:
  • Debt-to-Equity Ratio: 13.95%
  • Current Ratio: 4.46%
  • Quick Ratio: 3.76%
Sales & Book Value:
  • Annual Sales: $31.98 million
  • Price / Sales: 17.89
  • Book Value: ($0.08) per share
  • Price / Book: -60.00
Profitability:
  • Trailing EPS: ($1.50)
  • Net Income: $-161,090,000.00
  • Net Margins: -323.92%
  • Return on Equity: -10,954.62%
  • Return on Assets: -66.21%
Misc:
  • Employees: 193
  • Outstanding Shares: 119,220,000
 

Frequently Asked Questions for Keryx Biopharmaceuticals (NASDAQ:KERX)

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) posted its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The biopharmaceutical company earned $15 million during the quarter, compared to analyst estimates of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The company's revenue was up 138.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.39) earnings per share. View Keryx Biopharmaceuticals' Earnings History.

Where is Keryx Biopharmaceuticals' stock going? Where will Keryx Biopharmaceuticals' stock price be in 2017?

5 Wall Street analysts have issued 12 month price objectives for Keryx Biopharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Keryx Biopharmaceuticals' stock price to reach $7.00 in the next year. View Analyst Ratings for Keryx Biopharmaceuticals.

What are Wall Street analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Keryx’s loss in third-quarter 2017 was wider than expected while sales missed estimates. With Auryxia being the only approved product in Keryx’s portfolio, the company is entirely dependent on it for growth. Meanwhile, Auryxia faces stiff competition in the United States from existing players, apart from over-the-counter drugs like some calcium carbonate and metal-based products. Also, Keryx may face strong pricing pressure for Auryxia. In fact, the drug witnessed a sequential decline in sales in the quarter due to change in the payer mix as well as lower-than-expected growth in prescriptions. Consequently, shares of the company underperformed the industry. However, on a positive note, the FDA approval for the label expansion of Auryxia to treat adults with iron deficiency anemia (IDA) and chronic kidney disease, not on dialysis, might boost sales of the company, given that the IDA market holds great potential." (11/10/2017)
  • 2. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)

Who are some of Keryx Biopharmaceuticals' key competitors?

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the folowing people:

  • Michael W. Rogers, Chairman of the Board (Age 57)
  • Gregory Paul Madison, Chief Executive Officer, Director (Age 49)
  • Scott A. Holmes, Chief Financial Officer, Treasurer (Age 42)
  • Christine A. Carberry, Chief Operating Officer (Age 56)
  • Douglas M. Jermasek, Vice President of Marketing and Strategy
  • Brian R. Adams, General Counsel, Secretary (Age 43)
  • Lora Pike, Senior Director
  • John F. Neylan, Chief Medical Officer (Age 64)
  • Kevin J. Cameron, Independent Director (Age 48)
  • Mark J. Enyedy, Independent Director (Age 53)

Who owns Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.35%), Ameriprise Financial Inc. (0.87%), Bank of New York Mellon Corp (0.82%), Russell Investments Group Ltd. (0.64%), Old West Investment Management LLC (0.60%) and Monarch Partners Asset Management LLC (0.58%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes. View Institutional Ownership Trends for Keryx Biopharmaceuticals.

Who sold Keryx Biopharmaceuticals stock? Who is selling Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Ameriprise Financial Inc., Bristol Advisors LLC, New York State Common Retirement Fund, Old West Investment Management LLC and Rice Hall James & Associates LLC. Company insiders that have sold Keryx Biopharmaceuticals company stock in the last year include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes. View Insider Buying and Selling for Keryx Biopharmaceuticals.

Who bought Keryx Biopharmaceuticals stock? Who is buying Keryx Biopharmaceuticals stock?

Keryx Biopharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Monarch Partners Asset Management LLC, EAM Investors LLC, Perceptive Advisors LLC, Adell Harriman & Carpenter Inc., Schwab Charles Investment Management Inc., Chicago Equity Partners LLC and Engineers Gate Manager LP. View Insider Buying and Selling for Keryx Biopharmaceuticals.

How do I buy Keryx Biopharmaceuticals stock?

Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Keryx Biopharmaceuticals' stock price today?

One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $4.80.

How big of a company is Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals has a market capitalization of $568.81 million and generates $31.98 million in revenue each year. The biopharmaceutical company earns $-161,090,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Keryx Biopharmaceuticals employs 193 workers across the globe.

How can I contact Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals' mailing address is 1 Marina Park Dr, BOSTON, MA 02210-1832, United States. The biopharmaceutical company can be reached via phone at +1-617-4663500 or via email at [email protected]


MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Keryx Biopharmaceuticals (NASDAQ:KERX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $7.00 (45.83% upside)

Consensus Price Target History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Price Target History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017Stifel NicolausLower Price TargetHold$7.00 -> $5.00N/AView Rating Details
7/27/2017Maxim GroupSet Price TargetBuy$9.00HighView Rating Details
7/25/2017Morgan StanleyReiterated RatingEqual Weight$4.00 -> $7.00LowView Rating Details
7/25/2017Cowen and CompanyReiterated RatingMarket PerformMediumView Rating Details
1/11/2017Citigroup Inc.UpgradeSell -> Neutral$7.00N/AView Rating Details
11/19/2016FBR & CoReiterated RatingHoldN/AView Rating Details
9/8/2016JMP SecuritiesReiterated RatingOutperformN/AView Rating Details
8/2/2016Raymond James Financial, Inc.Boost Price TargetOutperform$7.00 -> $10.00N/AView Rating Details
8/2/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$9.00 -> $10.00N/AView Rating Details
8/2/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
3/29/2016BTIG ResearchReiterated RatingSell$2.50N/AView Rating Details
2/26/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralN/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Keryx Biopharmaceuticals (NASDAQ:KERX)

Earnings by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Earnings History by Quarter for Keryx Biopharmaceuticals (NASDAQ KERX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.17)($0.20)$18.88 million$15.00 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.17)($0.77)$14.51 million$15.10 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.18)($0.21)$10.19 million$11.82 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.25)($0.32)$9.65 million$9.53 millionViewListenView Earnings Details
11/9/2016Q316($0.22)($0.39)$5.53 million$6.30 millionViewListenView Earnings Details
8/1/2016Q216($0.28)($0.42)$8.60 million$9.30 millionViewListenView Earnings Details
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details
10/29/2015Q3 2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details
2/27/2015Q414($0.38)($0.44)$1.70 million$0.57 millionViewListenView Earnings Details
11/6/2014Q314($0.27)($0.38)$0.39 million$0.26 millionViewListenView Earnings Details
8/7/2014Q214($0.23)($0.24)$0.28 millionViewListenView Earnings Details
5/8/2014Q114($0.10)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
Current Year EPS Consensus Estimate: $-1.36 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS

Dividends

Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Keryx Biopharmaceuticals (NASDAQ KERX)

Insider Ownership Percentage: 2.58%
Institutional Ownership Percentage: 65.44%
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ KERX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/30/2017Brian AdamsGeneral CounselSell1,405$6.03$8,472.15View SEC Filing  
10/30/2017Greg MadisonInsiderSell4,055$6.03$24,451.65View SEC Filing  
10/30/2017Scott A. HolmesCFOSell2,582$6.03$15,569.46View SEC Filing  
10/23/2017John F. NeylanInsiderSell1,179$6.53$7,698.87View SEC Filing  
10/5/2017Brian AdamsGeneral CounselSell630$7.19$4,529.70View SEC Filing  
10/5/2017Greg MadisonInsiderSell895$7.19$6,435.05View SEC Filing  
7/31/2017John F. NeylanInsiderSell1,445$7.14$10,317.30View SEC Filing  
7/28/2017Scott A. HolmesCFOSell1,236$6.96$8,602.56View SEC Filing  
7/24/2017John F. NeylanInsiderSell1,214$7.27$8,825.78View SEC Filing  
7/5/2017Brian AdamsGeneral CounselSell641$7.67$4,916.47View SEC Filing  
7/5/2017Greg MadisonInsiderSell910$7.67$6,979.70View SEC Filing  
4/28/2017Scott A. HolmesCFOSell1,219$5.89$7,179.91View SEC Filing  
4/24/2017John F. NeylanInsiderSell1,209$5.73$6,927.57View SEC Filing  
4/17/2017Brian AdamsGeneral CounselSell1,090$5.75$6,267.50View SEC Filing  
4/5/2017Brian AdamsGeneral CounselSell642$5.80$3,723.60View SEC Filing  
4/5/2017Greg MadisonInsiderSell911$5.80$5,283.80View SEC Filing  
1/30/2017Brian AdamsGeneral CounselSell6,984$4.65$32,475.60View SEC Filing  
1/30/2017Greg MadisonInsiderSell18,248$4.65$84,853.20View SEC Filing  
1/30/2017Scott A. HolmesCFOSell8,447$4.65$39,278.55View SEC Filing  
1/23/2017John F. NeylanInsiderSell1,428$5.39$7,696.92View SEC Filing  
1/17/2017Brian AdamsVPSell1,265$6.24$7,893.60View SEC Filing  
1/5/2017Brian AdamsVPSell759$6.16$4,675.44View SEC Filing  
1/5/2017Greg MadisonInsiderSell1,077$6.16$6,634.32View SEC Filing  
10/28/2016Scott A. HolmesCFOSell1,237$4.44$5,492.28View SEC Filing  
10/24/2016John F. NeylanInsiderSell1,211$4.72$5,715.92View SEC Filing  
10/17/2016Brian AdamsVPSell1,106$4.86$5,375.16View SEC Filing  
10/5/2016Brian AdamsVPSell647$5.38$3,480.86View SEC Filing  
10/5/2016Greg MadisonInsiderSell917$5.38$4,933.46View SEC Filing  
8/9/2016Greg MadisonInsiderSell1,622$4.22$6,844.84View SEC Filing  
7/29/2016Scott A. HolmesCFOSell4,935$7.36$36,321.60View SEC Filing  
7/25/2016John F. NeylanInsiderSell1,217$7.43$9,042.31View SEC Filing  
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Keryx Biopharmaceuticals (NASDAQ KERX)

Source:
DateHeadline
Keryx: The Solution Is The Problem - Seeking AlphaKeryx: The Solution Is The Problem - Seeking Alpha
seekingalpha.com - November 19 at 7:02 PM
Technical Snapshots for These Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and TG ... - PR Newswire (press release)Technical Snapshots for These Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and TG ... - PR Newswire (press release)
www.prnewswire.com - November 17 at 10:31 AM
Contrasting Relypsa (RLYP) and Keryx Biopharmaceuticals (KERX)Contrasting Relypsa (RLYP) and Keryx Biopharmaceuticals (KERX)
www.americanbankingnews.com - November 16 at 5:08 PM
Keryx Biopharma Down 17% Despite Drug ApprovalKeryx Biopharma Down 17% Despite Drug Approval
finance.yahoo.com - November 15 at 3:46 AM
Keryx Biopharmaceuticals, Inc. (KERX) Receives Average Rating of "Hold" from AnalystsKeryx Biopharmaceuticals, Inc. (KERX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 13 at 9:34 PM
Keryx Biopharmaceuticals, Inc. (KERX) Cut to "Strong Sell" at ValuEngineKeryx Biopharmaceuticals, Inc. (KERX) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - November 11 at 6:18 PM
Keryx Biopharmaceuticals, Inc. (KERX) Cut to "Sell" at Zacks Investment ResearchKeryx Biopharmaceuticals, Inc. (KERX) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - November 10 at 12:16 PM
Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines - NasdaqKeryx (KERX) Q3 Loss Wider Than Expected, Stock Declines - Nasdaq
www.nasdaq.com - November 9 at 7:28 AM
Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results - GlobeNewswire (press release)Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 7:28 AM
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017 - GlobeNewswire (press release)Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017 - GlobeNewswire (press release)
globenewswire.com - November 9 at 7:28 AM
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017
finance.yahoo.com - November 9 at 7:28 AM
Corporate News Blog – Keryx Announces FDA Approval of Auryxia for Treatment of Iron Deficiency Anemia Patients with Chronic Kidney DiseaseCorporate News Blog – Keryx Announces FDA Approval of Auryxia for Treatment of Iron Deficiency Anemia Patients with Chronic Kidney Disease
finance.yahoo.com - November 9 at 7:28 AM
Keryx Biopharmaceuticals, Inc. (KERX) Releases Quarterly  Earnings Results, Misses Expectations By $0.03 EPSKeryx Biopharmaceuticals, Inc. (KERX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - November 8 at 2:23 PM
Keryx Biopharmaceuticals (KERX) CEO Gregory Madison on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaKeryx Biopharmaceuticals' (KERX) CEO Gregory Madison on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 11:23 AM
Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results   Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results   
finance.yahoo.com - November 8 at 11:23 AM
U.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on DialysisU.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
finance.yahoo.com - November 8 at 11:23 AM
Keryx Biopharma reports 3Q lossKeryx Biopharma reports 3Q loss
finance.yahoo.com - November 8 at 11:23 AM
Keryx Biopharmaceuticals (KERX) Announces FDA Approval of Auryxia Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis; Shares TumbleKeryx Biopharmaceuticals (KERX) Announces FDA Approval of Auryxia Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis; Shares Tumble
finance.yahoo.com - November 8 at 11:23 AM
Keryx (KERX) Posts Wider Q3 Loss, Lags Sales, Shares DownKeryx (KERX) Posts Wider Q3 Loss, Lags Sales, Shares Down
finance.yahoo.com - November 8 at 11:23 AM
Edited Transcript of KERX earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of KERX earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 8 at 11:23 AM
Despite FDA OK, Keryx Sinks on Gross-to-Net SurpriseDespite FDA OK, Keryx Sinks on Gross-to-Net Surprise
finance.yahoo.com - November 8 at 11:22 AM
Keryx Biopharma, Auryxia Presentations, Upcoming PDUFA Date and Analysts ReviewKeryx Biopharma, Auryxia Presentations, Upcoming PDUFA Date and Analysts Review
finance.yahoo.com - November 7 at 6:13 AM
Keryx Biopharmaceuticals (KERX) in Focus: Stock Moves 10.8% HigherKeryx Biopharmaceuticals (KERX) in Focus: Stock Moves 10.8% Higher
finance.yahoo.com - November 7 at 6:13 AM
Keryx Biopharmaceuticals, Inc. to Host Earnings CallKeryx Biopharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 6:13 AM
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't MatterKeryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
finance.yahoo.com - November 7 at 6:13 AM
Keryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ETKeryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ET
finance.yahoo.com - November 7 at 6:13 AM
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Heres Why That Doesnt MatterKeryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
www.fool.com - November 6 at 2:19 PM
Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASNs 2017 Kidney Week - GlobeNewswire (press release)Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASN's 2017 Kidney Week - GlobeNewswire (press release)
globenewswire.com - November 5 at 2:57 AM
Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASN’s 2017 Kidney WeekKeryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASN’s 2017 Kidney Week
finance.yahoo.com - November 5 at 2:57 AM
Keryx Biopharmaceuticals Announces Presentation of Post-Hoc Data From Phase 3 Study of Auryxia® (Ferric Citrate) in Adults With Iron Deficiency Anemia and Non-dialysis Dependent Chronic Kidney DiseaseKeryx Biopharmaceuticals Announces Presentation of Post-Hoc Data From Phase 3 Study of Auryxia® (Ferric Citrate) in Adults With Iron Deficiency Anemia and Non-dialysis Dependent Chronic Kidney Disease
finance.yahoo.com - November 3 at 12:35 PM
Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERXKey Predictions for Q3 Earnings Reports of MYL, HZNP & KERX
finance.yahoo.com - November 3 at 12:35 PM
Greg Madison Sells 4,055 Shares of Keryx Biopharmaceuticals, Inc. (KERX) StockGreg Madison Sells 4,055 Shares of Keryx Biopharmaceuticals, Inc. (KERX) Stock
www.americanbankingnews.com - October 31 at 6:00 PM
Scott A. Holmes Sells 2,582 Shares of Keryx Biopharmaceuticals, Inc. (KERX) StockScott A. Holmes Sells 2,582 Shares of Keryx Biopharmaceuticals, Inc. (KERX) Stock
www.americanbankingnews.com - October 31 at 6:00 PM
Keryx Biopharmaceuticals, Inc. (KERX) Set to Announce Quarterly Earnings on TuesdayKeryx Biopharmaceuticals, Inc. (KERX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 4:22 AM
Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2017 Financial Results on Monday, November 6, 2017Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2017 Financial Results on Monday, November 6, 2017
finance.yahoo.com - October 26 at 9:03 PM
Keryx Biopharmaceuticals Becomes Oversold (KERX)Keryx Biopharmaceuticals Becomes Oversold (KERX)
www.thestreet.com - October 23 at 7:53 PM
Financial Comparison: Agile Therapeutics (AGRX) & Keryx Biopharmaceuticals (KERX)Financial Comparison: Agile Therapeutics (AGRX) & Keryx Biopharmaceuticals (KERX)
www.americanbankingnews.com - October 23 at 4:32 AM
Keryx Biopharmaceuticals, Inc. (KERX) Given Average Rating of "Hold" by BrokeragesKeryx Biopharmaceuticals, Inc. (KERX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 19 at 8:46 PM
Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : October 16, 2017Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : October 16, 2017
finance.yahoo.com - October 16 at 7:43 PM
Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week ... - GlobeNewswire (press release)Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week ... - GlobeNewswire (press release)
globenewswire.com - October 13 at 8:12 PM
Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual MeetingKeryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual Meeting
feeds.benzinga.com - October 13 at 11:25 AM
KERX Crosses Above Average Analyst TargetKERX Crosses Above Average Analyst Target
www.thestreet.com - October 10 at 7:40 PM
Before You Buy Keryx Biopharmaceuticals Inc’s (KERX), You Should Consider ThisBefore You Buy Keryx Biopharmaceuticals Inc’s (KERX), You Should Consider This
finance.yahoo.com - October 10 at 7:40 PM
$18.80 Million in Sales Expected for Keryx Biopharmaceuticals, Inc. (KERX) This Quarter$18.80 Million in Sales Expected for Keryx Biopharmaceuticals, Inc. (KERX) This Quarter
www.americanbankingnews.com - October 10 at 8:48 AM
Why the Bears Are Wrong About Keryx Biopharmaceuticals StockWhy the Bears Are Wrong About Keryx Biopharmaceuticals Stock
www.fool.com - October 10 at 8:00 AM
Zacks: Analysts Expect Keryx Biopharmaceuticals, Inc. (KERX) Will Announce Earnings of -$0.17 Per ShareZacks: Analysts Expect Keryx Biopharmaceuticals, Inc. (KERX) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - October 8 at 2:24 PM
Keryx, Upcoming PDUFA Action on Label Expansion for AuryxiaKeryx, Upcoming PDUFA Action on Label Expansion for Auryxia
finance.yahoo.com - October 6 at 2:22 AM
Keryx Focuses on Kidney Drug Auryxia Despite Generic ThreatKeryx Focuses on Kidney Drug Auryxia Despite Generic Threat
www.zacks.com - September 29 at 9:39 AM
Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : September 26, 2017Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : September 26, 2017
finance.yahoo.com - September 26 at 10:04 AM
Heres Why These 3 Biotech Stocks Might Stop Rallying (Revised) - NasdaqHere's Why These 3 Biotech Stocks Might Stop Rallying (Revised) - Nasdaq
www.nasdaq.com - September 25 at 6:48 PM

Social Media

Financials

Chart

Keryx Biopharmaceuticals (NASDAQ KERX) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.